Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Avidin
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Avidin

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 4 min read

A specific protein in egg albumin that interacts with biotin to render it unavailable to mammals, thereby producing biotin deficiency.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (861 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A specific protein in egg albumin that interacts with biotin to render it unavailable to mammals, thereby producing biotin deficiency.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Where it fits in the MeSH classification

Broader topics
Glycoproteins; Ovalbumin
See also
Biotin

Related concepts

  • Biotin

Research landscape

PubMed indexes 3,392 records tagged with the MeSH heading “Avidin” (counts retrieved 2026-10-31). 186 of them (5.5%) were published from 2020 onward, and the busiest period so far is through 1999 with 1,589 records.

Reviews account for 107 records (3.2%) and meta-analyses for 0. Randomized controlled trials number 5 (0.1%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 1,589 records; 2000-2009: 887 records; 2010-2019: 730 records; 2020 onward: 186 records1,589through 19998872000-20097302010-20191862020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19991,589
2000-2009887
2010-2019730
2020 onward186
Share of records by publication typeReviews: 3.2 percent; Meta-analyses: 0.0 percent; Randomized controlled trials: 0.1 percentReviews3.2% (107)Meta-analyses0.0% (0)Randomized controlled trials0.1% (5)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 3,392 PubMed records
TypeRecordsShare
Reviews1073.2%
Meta-analyses00.0%
Randomized controlled trials50.1%

Method: PubMed query "Avidin"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity
Chinol M, Casalini P, Maggiolo M, Canevari S, Omodeo ES, Caliceti P, et al.
1998Research article
Design not recorded in structured metadata
86cc by
PMID 9683292 · DOI · PMC2062912
Detailed characterization of the solution kinetics and thermodynamics of biotin, biocytin and HABA binding to avidin and streptavidin
Delgadillo RF, Mueser TC, Zaleta-Rivera K, Carnes KA, González-Valdez J, Parkhurst LJ
2019Research article
Design not recorded in structured metadata
34cc by
PMID 30818336 · DOI · PMC6394990
Advanced surface passivation for high-sensitivity studies of biomolecular condensates
Yao RW, Rosen MK
2024Research article
Design not recorded in structured metadata
29cc by
PMID 38781207 · DOI · PMC11145189
Modular Assembly of Dynamic Polymer Networks From Heteroaffinity Cross-Links to Multivalent Proteins
Dai T, Qiu Y, Leon Hernandez KM, Chan W, Mejia K, Nemeria N, et al.
2026Research article
Design not recorded in structured metadata
0cc by
PMID 41645662 · DOI · PMC13098475

Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity [1]

Research article Chinol M, Casalini P, Maggiolo M, Canevari S, Omodeo ES, Caliceti P, et al. · · 1998 · cited 86 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Pretargeting techniques using the avidin-biotin system have shown encouraging results in both diagnostic and therapeutic clinical trials.
Closing excerpt
In conclusion, the conjugation of avidin to PEG chains (n = 7) originates a compound with a suitable blood clearance, low immunogenicity and concurrent low cross-reactivity with avidin.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (224 words)

Pretargeting techniques using the avidin-biotin system have shown encouraging results in both diagnostic and therapeutic clinical trials. It has been shown that in cancer therapy the ideal agent to be used for pretargeting should have a plasma half-life longer than avidin and lower immunogenicity than streptavidin in order for these procedures to be applied safely and repeatedly in patients. We prepared a recombinant form of avidin with no carbohydrates and avidins, biochemically modified either by decreasing the positive charges with succinic anhydride or by linking polyethylene glycol (PEG) at three different molar ratios and evaluated their in vivo behaviour after i.p. administration in mice. The succinylation and PEGylation of avidin increased the plasma half-life proportionally to the degree of protein modification. The procedures, however, affected the biotin binding to some extent. The biodistribution studies showed that, for all six time points (ranging from 20 min to 18 h post-injection), the liver and kidney to blood ratios were lower for PEGylated avidins than native, recombinant and succinyl avidin. Recombinant and low PEGylated avidin evoked an immune response in all mice after at least three injections. Native, recombinant and succinyl avidins showed higher serum titres than PEGylated avidins. In conclusion, the conjugation of avidin to PEG chains (n = 7) originates a compound with a suitable blood clearance, low immunogenicity and concurrent low cross-reactivity with avidin.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 9683292 · DOI · PMC2062912

Detailed characterization of the solution kinetics and thermodynamics of biotin, biocytin and HABA binding to avidin and streptavidin [2]

Research article Delgadillo RF, Mueser TC, Zaleta-Rivera K, Carnes KA, González-Valdez J, Parkhurst LJ · · 2019 · cited 34 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The high affinity (KD ~ 10-15 M) of biotin for avidin and streptavidin is the essential component in a multitude of bioassays with many experiments using biotin modifications to invoke coupling.
Closing excerpt
Our new understanding and description of the kinetics, thermodynamics, and spectroscopic parameters for these complexes will help to improve purification efficiencies, molecule detection, and drug screening assays or find new applications.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (262 words)

The high affinity (KD ~ 10-15 M) of biotin for avidin and streptavidin is the essential component in a multitude of bioassays with many experiments using biotin modifications to invoke coupling. Equilibration times suggested for these assays assume that the association rate constant (kon) is approximately diffusion limited (109 M-1s-1) but recent single molecule and surface binding studies indicate that they are slower than expected (105 to 107 M-1s-1). In this study, we asked whether these reactions in solution are diffusion controlled, which reaction model and thermodynamic cycle describes the complex formation, and if there are any functional differences between avidin and streptavidin. We have studied the biotin association by two stopped-flow methodologies using labeled and unlabeled probes: I) fluorescent probes attached to biotin and biocytin; and II) unlabeled biotin and HABA, 2-(4'-hydroxyazobenzene)-benzoic acid. Both native avidin and streptavidin are homo-tetrameric and the association data show no cooperativity between the binding sites. The kon values of streptavidin are faster than avidin but slower than expected for a diffusion limited reaction in both complexes. Moreover, the Arrhenius plots of the kon values revealed strong temperature dependence with large activation energies (6-15 kcal/mol) that do not correspond to a diffusion limited process (3-4 kcal/mol). Accordingly, we propose a simple reaction model with a single transition state for non-immobilized reactants whose forward thermodynamic parameters complete the thermodynamic cycle, in agreement with previously reported studies. Our new understanding and description of the kinetics, thermodynamics, and spectroscopic parameters for these complexes will help to improve purification efficiencies, molecule detection, and drug screening assays or find new applications.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30818336 · DOI · PMC6394990

Advanced surface passivation for high-sensitivity studies of biomolecular condensates [3]

Research article Yao RW, Rosen MK · · 2024 · cited 29 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Biomolecular condensates are cellular compartments that concentrate biomolecules without an encapsulating membrane.
Closing excerpt
Our observations suggest a potential heterogeneity in the distribution of available polySIM-binding sites within the condensates.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (190 words)

Biomolecular condensates are cellular compartments that concentrate biomolecules without an encapsulating membrane. In recent years, significant advances have been made in the understanding of condensates through biochemical reconstitution and microscopic detection of these structures. Quantitative visualization and biochemical assays of biomolecular condensates rely on surface passivation to minimize background and artifacts due to condensate adhesion. However, the challenge of undesired interactions between condensates and glass surfaces, which can alter material properties and impair observational accuracy, remains a critical hurdle. Here, we introduce an efficient, broadly applicable, and simple passivation method employing self-assembly of the surfactant Pluronic F127 (PF127). The method greatly reduces nonspecific binding across a range of condensates systems for both phase-separated droplets and biomolecules in dilute phase. Additionally, by integrating PF127 passivation with the Biotin-NeutrAvidin system, we achieve controlled multipoint attachment of condensates to surfaces. This not only preserves condensate properties but also facilitates long-time fluorescence recovery after photobleaching imaging and high-precision single-molecule analyses. Using this method, we have explored the dynamics of polySIM molecules within polySUMO/polySIM condensates at the single-molecule level. Our observations suggest a potential heterogeneity in the distribution of available polySIM-binding sites within the condensates.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38781207 · DOI · PMC11145189

Modular Assembly of Dynamic Polymer Networks From Heteroaffinity Cross-Links to Multivalent Proteins [4]

Research article Dai T, Qiu Y, Leon Hernandez KM, Chan W, Mejia K, Nemeria N, et al. · · 2026

Abstract reading summary — source excerpts
Opening excerpt
Dynamic polymer networks (DPN) leverage transient cross-linking to yield macroscopic materials that exhibit self-healing and environmentally responsive behaviors.
Closing excerpt
We also develop a pH-sensitive HAX that yields DPNs with robust pH-responsive assembly dynamics, and demonstrate how this DPN can be made into a magnetically responsive, molecular delivery system to low-pH regions, such as tumor microenvironments.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (185 words)

Dynamic polymer networks (DPN) leverage transient cross-linking to yield macroscopic materials that exhibit self-healing and environmentally responsive behaviors. Despite the broad scope of chemical interactions available for cross-linking, imbuing those transient interactions into biologically compatible materials is difficult because many chemistries are incompatible with aqueous conditions, and it is difficult to tune preexisting biological interactions that have evolved over millions of years for specificity. To enable the assembly of chemically tunable and biologically compatible DPNs, we have developed a set of bifunctional, heteroaffinity cross-linkers (HAX) where the reactive moieties have different binding affinities to the same binding sites of an oligomeric protein. The use of cross-linking moieties with vastly different dissociation rates enables purification of protein modules with monodisperse HAX valencies. Assembly of DPNs from stoichiometrically identical pairs of protein modules then yields unique, metastable, nonequilibrium network topologies. Here, we demonstrate these concepts using the well-studied avidin-biotin interaction chemistry. We also develop a pH-sensitive HAX that yields DPNs with robust pH-responsive assembly dynamics, and demonstrate how this DPN can be made into a magnetically responsive, molecular delivery system to low-pH regions, such as tumor microenvironments.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41645662 · DOI · PMC13098475

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article The avidin-biotin complex in bioanalytical applications [5]
    Wilchek M, Bayer EA · Anal Biochem · 1988 · cited 494 times (Europe PMC)
  • Research article The biotin-(strept)avidin system: principles and applications in biotechnology [6]
    Diamandis EP, Christopoulos TK · Clin Chem · 1991 · cited 339 times (Europe PMC)
  • Research article Introduction to avidin-biotin technology [7]
    Wilchek M, Bayer EA · Methods Enzymol · 1990 · cited 271 times (Europe PMC)
  • Research article Genetically engineered avidins and streptavidins [8]
    Laitinen OH, Hytönen VP, Nordlund HR, Kulomaa MS · Cell Mol Life Sci · 2006 · cited 204 times (Europe PMC)
  • Research article The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis [9]
    Jain A, Cheng K · J Control Release · 2017 · cited 183 times (Europe PMC)
  • Research article Avidin-biotin technology in targeted therapy [10]
    Lesch HP, Kaikkonen MU, Pikkarainen JT, Ylä-Herttuala S · Expert Opin Drug Deliv · 2010 · cited 139 times (Europe PMC)

References

  1. Chinol M, Casalini P, Maggiolo M, Canevari S, Omodeo ES, Caliceti P, et al.. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. . 1998. PMID 9683292 · DOI · PMC2062912
  2. Delgadillo RF, Mueser TC, Zaleta-Rivera K, Carnes KA, González-Valdez J, Parkhurst LJ. Detailed characterization of the solution kinetics and thermodynamics of biotin, biocytin and HABA binding to avidin and streptavidin. . 2019. PMID 30818336 · DOI · PMC6394990
  3. Yao RW, Rosen MK. Advanced surface passivation for high-sensitivity studies of biomolecular condensates. . 2024. PMID 38781207 · DOI · PMC11145189
  4. Dai T, Qiu Y, Leon Hernandez KM, Chan W, Mejia K, Nemeria N, et al.. Modular Assembly of Dynamic Polymer Networks From Heteroaffinity Cross-Links to Multivalent Proteins. . 2026. PMID 41645662 · DOI · PMC13098475
  5. Wilchek M, Bayer EA. The avidin-biotin complex in bioanalytical applications. Anal Biochem. 1988. PMID 3044183 · DOI
  6. Diamandis EP, Christopoulos TK. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem. 1991. PMID 2032315 · DOI
  7. Wilchek M, Bayer EA. Introduction to avidin-biotin technology. Methods Enzymol. 1990. PMID 2201884 · DOI
  8. Laitinen OH, Hytönen VP, Nordlund HR, Kulomaa MS. Genetically engineered avidins and streptavidins. Cell Mol Life Sci. 2006. PMID 17086379 · DOI · PMC11136427
  9. Jain A, Cheng K. The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis. J Control Release. 2017. PMID 27865853 · DOI · PMC5222781
  10. Lesch HP, Kaikkonen MU, Pikkarainen JT, Ylä-Herttuala S. Avidin-biotin technology in targeted therapy. Expert Opin Drug Deliv. 2010. PMID 20233034 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • alpha 1-AntitrypsinDrugs and Chemicals
  • Anti-Mullerian HormoneDrugs and Chemicals
  • beta 2-MicroglobulinDrugs and Chemicals
  • CadherinsDrugs and Chemicals
  • Carcinoembryonic AntigenDrugs and Chemicals
  • CD40 LigandDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

3,392
PubMed records on this heading
5%
published since 2020
107
review articles
5
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • alpha 1-AntitrypsinDrugs and Chemicals
  • Anti-Mullerian HormoneDrugs and Chemicals
  • beta 2-MicroglobulinDrugs and Chemicals
  • CadherinsDrugs and Chemicals
  • Carcinoembryonic AntigenDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support